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Most long-term survivors with non-small cell lung cancer (NSCLC) 
are patients having had a complete surgical resection of their tumour; 
however this is only achievable in about 30 % of the patients. Even in 
this highly selected group of patients, there is a high risk of both local 
and distant failure. Adjuvant treatments such as chemotherapy and 
radiotherapy have therefore been evaluated in prospective trials over 
the past 30 years, and both have been controversial for years. However 
adjuvant chemotherapy has recently become part of the standard of 
care in stage II and III completely resected patients. Whereas individual 
trials comparing surgery alone to surgery + adjuvant CT could not 
achieve any signiﬁcant difference, the meta-analysis published in 1995 
showed a modest survival beneﬁt of 5% in completely resected patients 
having received post-operative cisplatin based adjuvant chemotherapy 
compared to patients without chemotherapy [Non-Small Cell Lung 
Cancer Collaborative Group, 1995]. Several large trials evaluating 
platin based combination chemotherapy were launched thereafter and 
have now been published. The range of the survival beneﬁt at 5 years 
observed with chemotherapy varies between 4 % and 15% [Scagliotti 
2003,IALT 2004, Hamada 2004, Hotta 2004, Strauss 2004, Sedrakyan 
2004, Winton 2004, Waller 2004, Douillard 2006, Pignon 2006]. 
In view of the high proportion of the patients (20 to 40%) still suffering 
from local tumour recurrence after a complete resection and adjuvant 
chemotherapy, there is a new interest in post-operative radiotherapy 
(PORT) which has been quite controversial in the past 10 years. The 
PORT Meta-analysis Trialists Group analysed individual patient data 
from 2128 patients from nine randomised trials that compared post-
operative radiotherapy with surgery alone by intention to treat [PORT 
Meta-analysis Trialists Group, 1998]. The results indicated that post-
operative radiotherapy had a signiﬁcant detrimental effect on survival. 
There were 707 deaths among 1056 patients assigned to the postopera-
tive radiotherapy arm versus 661 deaths among 1072 patients included 
in the surgery alone arm. This represented a 21% relative increase in 
the risk of death or to an absolute decrease of 7% at 2 years, reduc-
ing the overall survival from 55 to 48% (mortality hazard ratio, 1.21; 
95% conﬁdence interval [CI], 1.08ó1.34; p = 0.001). Subset analyses 
suggested that PORT could be deleterious in terms of overall survival, 
predominantly, among patients who had a complete resection and no 
mediastinal involvement (either pN0 or pN1). However they could 
observe a 24% relative reduction of local recurrence rate (all stages 
together), so that the question of post-operative radiotherapy in pN2 
who have a high local recurrence rate remained valid and could warrant 
further research. An update of this meta-analysis with one additional 
trial was recently published [Burdett and Stewart et al, 2005; Trodella 
and al, 2005]. They conﬁrmed the earlier results that PORT decreased 
the survival at two years by 6 % (52 % vs. 58 %). 
This meta-analysis has been criticized because radiotherapy techniques 
used were considered suboptimal, resulting in poorer results, higher 
morbidity and mortality rates in the PORT arm than in more recent 
studies. Most of the studies did not use CT scan based dosimetry. It 
should be stressed that seven of the nine trials included patients treated 
with Cobalt-60 equipment, which is known to increase morbidity. Sev-
eral authors have underlined the importance of the radiation technique 
to decrease this risk. 
Since the publication of the meta-analysis, only one randomised phase 
III trial has addressed the PORT issue. However, in this north-american 
intergroup study initiated by ECOG (Eastern Cooperative Oncology 
Group), the control arm was not surgery alone as in the trials included 
in the meta-analysis [Keller et al, 2000]. Post-operative adjuvant radio-
therapy considered as the control arm was compared to adjuvant radio-
therapy with concomitant chemotherapy in 488 stage II and III patients. 
There was no difference in terms of survival or patterns of recurrence 
between the 2 groups (3-year survival rate of 50% in the post operative 
chemoradiation arm and 52% in the PORT arm). There was a higher 
rate of serious side effects in the concomitant CT-RT arm. In terms 
of late toxicity, the 4-year actuarial rate of death from intercurrent 
disease (DID) for patients treated with PORT was 12,9%. Thus with 
more modern radiotherapy, the risk of late toxicity seems to decrease 
as this rate is not signiﬁcantly different from the 10,1% expected rate 
of DID observed in a matched control population for age and gender 
and corrected for smoking status [Wakelee et al, 2005]. Other phase II 
studies have reported interesting results with post-operative concomi-
tant chemoradiation [Bradley 2005]. However, after the results of the 
ECOG trial, post-operative concomitant chemoradiation should not be 
recommended outside of a trial. 
More recently, Lally and al have reported a retrospective study on 
postoperative radiotherapy in non-small-cell lung cancer, based on a 
population-based cohort of 7465 stage II and III patients who had sur-
gery [Lally et al, 2006]. They have selected from the SEER database, 
patients treated between 1988 and 2002, out of which 47% received 
PORT, supposedly with linear accelerators. The use of PORT did not 
have an impact on survival; however in the subset analysis according 
to nodal status, they come to the same conclusions as the meta-analysis 
for patients with N0 and N1 nodal disease: a signiﬁcant decreased sur-
vival in case of PORT. Among N2 patients, a beneﬁt in 5-year survival 
was observed with surgery and PORT as compared to surgery (20% vs 
27%). As the study was not randomized, one should be cautious with 
conclusions and the patients who received PORT may have a different 
prognosis than those who did not. The ANITA trial also analysed the 
impact of radiotherapy among N1 and N2 patients whether they had 
or had not radiotherapy according to randomization [Douillard, 2006]. 
In N2 patients, the best results were observed in patients who had se-
quentially chemotherapy and PORT. The authors concluded that a new 
randomized trial could at best address this issue. 
So most studies agree that patients who could potentially beneﬁt from 
mediastinal radiotherapy are patients with N2 disease, at higher risk of 
local failure. Patients who receive preoperative chemotherapy for clini-
cal mediastinal involvement represents another category of patients for 
whom the role of post-operative radiotherapy has not been well estab-
lished. Several retrospective studies have indeed suggested a beneﬁt in 
terms of survival in favour of pre-operative chemotherapy for patients 
with mediastinal nodal involvement. Two randomized small studies, 
controversial because of their size, conﬁrmed these results, but a larger 
trial could not conﬁrm these results for the sub-group of N2 patients 
[Rosell et al, 1994; Roth et al, 1994; Depierre et al, 2002]. In a phase 
II study by Betticher et al, reporting long term results in patients with 
proven N2 nodal involvement, 60% had a local recurrence after neoad-
juvant chemotherapy followed by surgery [Betticher 2006]. Post-opera-
tive radiotherapy should therefore also be discussed in patients with 
initial N2 nodal involvement whatever their response to chemotherapy. 
At present, based on level 1 evidence, patients who have had a com-
plete resection of the primary tumor with mediastinal lymph node 
dissection showing no mediastinal involvement (pN0 and pN1) should 
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not have PORT. It seems important to evaluate modern post-operative 
radiotherapy in randomised trials as the number of patients with nodal 
involvement is increasing because of better surgery and the recent posi-
tive results of adjuvant chemotherapy. As in breast cancer or rectal can-
cer, it is time to better establish the role of post-operative radiotherapy 
in such a frequent tumour as lung cancer. A large, multi-institutional 
European phase III trial Lung ART (Lung Adjuvant Radiotherapy Trial) 
joint effort of several groups: IFCT, EORTC lung and radiation oncol-
ogy group, LARS-G and FNCLCC will soon start comparing confor-
mal PORT to no PORT, and will include patients who have proven N2 
disease and complete resection whether they have had or not, adjuvant 
or neo-adjuvant chemotherapy (Le Pechoux et al, 2007]. 
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It is clear that only some patients beneﬁt from systemic adjuvant 
therapy. This is the group of patients who have residual micrometas-
tases that are sensitive to adjuvant therapy. Patients with R0 resection 
of their tumor, without micrometastases are cured with local/regional 
therapy, whereas those with residual micrometastases that are resistant 
to adjuvant therapy do not respond to adjuvant therapy. There is there-
fore a need to identify factors that would allow for the identiﬁcation of 
patients most likely to beneﬁt from adjuvant chemotherapy. 
A potential predictive marker of bone metastases has recently been 
identiﬁed in patients with completely resected NSCLC that is also as-
sociated with survival outcome [1]. We investigated the presence of 10 
different markers involved in bone resorption or development of metas-
tases in 30 patients with resected NSCLC who subsequently developed 
bone metastases, and compared the results of this patient group with 
those of 30 patients with resected NSCLC without metastases and of 
26 patients with resected NSCLC who developed non-bone metastases. 
The expression of bone sialoprotein (BSP) was strongly correlated with 
the development of bone metastases (p < 0.001). Median survival was 
signiﬁcantly shorter in patients expressing BSP compared with those 
not expressing BSP (25 vs 39 months, p = 0.02) (Fig. 1). These data 
suggest that patients with tumors expressing BSP are at high risk of 
developing bone metastases and may therefore be more likely to beneﬁt 
from adjuvant chemotherapy or other preventive treatments. 
Another approach to identifying patients most likely to beneﬁt from ad-
juvant therapy is to use pharmacogenomics. This involves the analysis 
of molecular markers in tumors at the genetic level using polymerase 
chain reaction (PCR) techniques to analyze gene mutations and/or the 
level of gene expression. Various genetic markers that are predictive of 
increased or decreased sensitivity to various cytotoxic agents have been 
identiﬁed (Table 2) [2-4]. 
We performed a retrospective analysis of the expression of three genes 
and their potential correlation with survival in patients with advanced 
NSCLC treated with gemcitabine or gemcitabine/cisplatin [4]. The 
expression levels of excision repair cross-complementation 1 (ERCC1), 
ribonucleotide reductase M1 (RRM1) and epidermal growth factor 
receptor (EGFR) were determined by real-time PCR from 70 forma-
lin-ﬁxed, parafﬁn-embedded bronchoscopic/ﬁne-needle aspiration 
biopsies. ERCC1 and RRM1 but not EFGR were strongly correlated 
with overall survival; low levels of ERCC1 and RRM1 expression were 
associated with a signiﬁcantly longer survival compared to patients 
with higher levels of expression of these two genes. These data suggest 
that ERCC1 and RRM1 are appropriate genetic markers that could be 
used to select patients likely to beneﬁt from adjuvant therapy. Indeed, 
this approach is being used in an ongoing study in patients with stage 
IIIB/IV disease in which patients receive 1 of 4 different chemotherapy 
regimens according to the level of expression of RRM1 and ERCC1 
on their tumors. This approach is expected to yield a superior overall 
survival compared with historical data in this patient population. 
Another retrospective study investigated whether the presence of the 
genetic marker ERCC1 could be used to predict if a patient will beneﬁt 
from adjuvant chemotherapy compared with no further treatment [5]. 
This study analyzed data from the IALT in which patients were ran-
domized to receive cisplatin-based chemotherapy or observation. The 
study found that with adjuvant chemotherapy, survival was signiﬁcant-
ly longer in patients with ERCC1-negative tumors (adjusted HR 0.65, 
95% CI 0.50-0.86, p = 0.002), but not in patients with ERCC1-positive 
tumors (adjusted HR 1.14, 95% CI 0.84-1.55, p = 0.40) [13]. However, 
for patients who did not receive adjuvant chemotherapy, survival was 
signiﬁcantly longer in those with ERCC1-positive tumors compared 
to those with ERCC1-negative tumors (adjusted HR 0.66, 95% CI 
0.49-0.90, p = 0.009). Thus, ERCC1 expression may be an independent 
predictor of the beneﬁt of chemotherapy in patients with NSCLC.
The use of pharmacogenomics to predict response to therapy has 
been taken a step further by Potti et al. who have developed a model 
to predict therapeutic outcome based on gene expression proﬁles [6]. 
This technique involves analysis of total RNA from tumor cells, rather 
than following the expression of particular genes. Using this method, 
the authors developed a model that predicted disease recurrence with 
an overall accuracy of 93%, compared with 64% for a model based 
on clinical parameters (age, sex, tumor diameter, stage of disease, 
histological subtype and smoking history). When the accuracy of the 
pharmacogenomic model was assessed using data from 2 further stud-
ies, the accuracy was found to be 79% and 72%, thus validating the 
model. These data suggest that analysis of gene expression proﬁles can 
be used to predict patients for whom adjuvant chemotherapy may be 
appropriate.
This study also investigated whether the model based on gene expres-
sion proﬁles could be used to identify patients with stage IA disease 
at risk of recurrence. Previous studies have shown that approximately 
25% of patients with stage IA disease have disease recurrence within 5 
years, but markers for identifying such patients have not been devel-
oped. In this study, the model of gene expression proﬁles was used 
to identify patients with stage IA disease with a high or low risk of 
recurrence. Kaplan-Meier survival plots for the two subgroups revealed 
a 4-year survival of less than 10% for the high-risk group compared 
with approximately 90% for the low-risk group. These data suggest that 
analysis of gene expression proﬁles can be used to identify high- and 
low-risk groups of patients with stage IA disease. This information 
could help identify patients with stage IA disease for whom adjuvant 
chemotherapy may be appropriate. 
On the basis of the ﬁndings from this study, the CALGB (study 30506) 
has developed a randomized phase II trial in which 138 patients with 
operable stage I disease will be assigned to a predicted outcome of 
low- or high-risk of recurrence by gene expression analysis. Patients 
identiﬁed as low risk will be observed according to standard practice. 
Those identiﬁed as high risk will be randomized to either adjuvant 
chemotherapy or observation only. 
